HGH fragment analogue (C-terminal lipolytic fragment research)
AOD-9604
Modified fragment of the C-terminus of growth hormone investigated for lipolytic signalling without full GH- growth programmes.
Primary Mechanism of Action
Clinical / Scientific
AOD-9604 is a modified hGH 177–191 region analogue studied for fat-metabolism signalling. It was designed to retain some lipolytic activity while avoiding full IGF-1 axis stimulation. Clinical development did not produce a widely approved anti-obesity drug.
Pathway Targets
Lipolytic signalling
Scientific explanation
Experimental fat-metabolism pathway effects.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: Lipolytic signalling
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Adipocyte lipolysis pathways | Fragment signalling (models) | Energy store mobilisation | Preclinical / investigational |
In Plain Language
AOD-9604 is a small piece of growth-hormone sequence studied for fat-burning signals without the full growth-hormone growth effect. It remains a research analogue, not a proven weight-loss medicine.
Compounds Sharing Pathways
Other library compounds whose structured pathway data overlap this ingredient. Shared pathways are not combination recommendations.
Lipolytic signalling
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.